相关实验视频

Updated: Jul 15, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

乳杆菌发酵 (Lactobacillus fermentum) 缓解由低剂量次慢性微囊素-LR暴露引起的结肠直肠炎症

Yue Yang^1,2, Cong Wen³, Shuilin Zheng⁴

¹The Key Laboratory of Typical Environmental Pollution and Health Hazards of Hunan Province, Department of Epidemiology and Health Statistics, School of Public Health, Hengyang Medical School, University of South China, Hengyang 421001, China.

|September 27, 2023

概括

益生菌,特别是Lactobacillus fermentum,可以减轻微囊素-LR (MC-LR) 污染引起的肠道损伤. 这种有益的细菌通过抑制CSF1R信号通路来减少炎症,为MC-LR诱导的肠道损伤提供了潜在的治疗方法.

科学领域:

环境科学环境科学
微生物学微生物学
毒理学毒理学毒理学

背景情况:

微素-LR (MC-LR) 污染对水生态系统和公共卫生构成全球威胁.
暴露于MC-LR与肠道损伤有关,但缺乏有效的治疗方法.
益生菌在各种疾病中显示出治疗潜力,但它们在MC-LR诱导的肠道损伤中的作用尚未被探索.

研究的目的:

研究益生菌在缓解MC-LR诱导的肠道毒性的潜力.
阐明益生菌可以防止MC-LR危害的潜在机制.
为了确定与肠道中MC-LR暴露相关的特定微生物变化.

主要方法:

在小鼠模型中,亚慢性低剂量MC-LR暴露.
结直肠组织的组织病理学分析 (HE染色).
炎症因素的基因表达分析 (qPCR).
对CSF1R信号通路的蛋白质分析 (WB).
便样本的微生物测序.
在体外同时治疗的模型.

主要成果:

MC-LR诱导结直肠炎症,增加炎症因子,并激活CSF1R通路.
暴露于MC-LR显著降低了*乳杆菌*物种的丰度.
*Lactobacillus fermentum*联合治疗减轻了MC-LR诱导的炎症,并抑制了CSF1R通路的激活.

结论:

*Lactobacillus fermentum*显示出对MC-LR诱导的肠炎的保护作用.
该机制涉及通过L. fermentum*抑制CSF1R信号通路.
这项研究为开发基于益生菌的策略来对抗MC-LR相关的肠道疾病提供了基础.

关键词:

牛乳杆菌发酵 (Lactobacillus fermentum) 是一种植物.结肠直肠炎症是一种炎症.肠道疾病肠道疾病微囊素-LR的使用方法益生菌是一种益生菌.

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells

Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells

Published on: June 13, 2020

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...